NCT00669162View on ClinicalTrials.gov

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

April 30, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel

20mg/m2 IV weekly for 7 weeks

RADIATION

Radiation Therapy

66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx

DRUG

Casodex and Zoladex (or Lupron)

Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT00669162 - Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer | Biotech Hunter | Biotech Hunter